One To Watch
Aptevo Therapeutics
Company Overview
A Seattle-based clinical-stage biotechnology company building a portfolio of CD3-engaging multispecific antibodies, with lead asset mipletamig posting an 81% CR/CRi rate in frontline AML without cytokine release syndrome. Aptevo has assembled five CD3-engaging assets spanning hematologic malignancies and solid tumors, pursuing a platform bet that T-cell redirection can be made safer and broader than first-generation bispecifics demonstrated. The absence of dose-limiting toxicities or cytokine release syndrome in frontline AML patients to date is the data point that defines the current investment thesis.
Headquarters and Global Presence
Aptevo Therapeutics is headquartered in Seattle, Washington. The company operates as an independent, publicly traded US biotechnology corporation following its spin-off from Emergent BioSolutions.
Founding and History
Aptevo was established as an independent, publicly traded company following the completion of its spin-off from Emergent BioSolutions, a transaction reported in June 2016. Marvin White served as President and CEO from 2016, steering the company through the transition to a multispecific antibody platform focus. In April 2026, White retired to become Executive Chair, with COO Jeff Lamothe stepping up to President and CEO. The January 2026 closing of a $60 million equity line of credit with Yorkville Advisors marked a significant financing milestone, extending the runway into 2029.
Therapy Areas and Focus
Aptevo's primary focus is hematologic malignancies, led by acute myeloid leukemia, with a secondary expansion into solid tumors via PSMA- and Nectin-4-targeting assets. AML in patients ineligible for intensive chemotherapy represents a population with limited options, where the venetoclax-azacitidine backbone has become standard but response durability remains a persistent clinical problem. Adding a CD123-targeting T-cell redirector to that backbone is the mechanistic hypothesis underpinning the RAINIER trial.
Technology Platforms and Modalities
Aptevo's platform generates bispecific and trispecific antibodies that engage CD3 on T cells while simultaneously binding tumor-associated antigens, physically recruiting cytotoxic T cells to cancer cells. The ADAPTIR platform architecture is designed to minimize the cytokine storm risk that has historically limited CD3-bispecific tolerability, particularly at doses required for solid tumor penetration. The portfolio's two trispecific assets, APVO451 and APVO452, represent an extension of this approach toward co-stimulatory or dual-antigen targeting, though both remain preclinical.
Key Pipeline and Programs
Mipletamig is Aptevo's lead asset: a first-in-class CD123 x CD3 bispecific antibody evaluated in the RAINIER trial, a multi-center Phase Ib/II study in combination with venetoclax and azacitidine for newly diagnosed AML patients ineligible for intensive chemotherapy. As of the Q1 2026 update, the combination has produced an 87% clinical benefit rate and an 81% complete remission or CRi rate in the frontline setting, with no cytokine release syndrome observed and no dose-limiting toxicities reported. RAINIER is on track to complete dose selection and advance to Phase II by year-end 2026.
APVO442 is a PSMA x CD3 bispecific targeting prostate cancer, taking Aptevo's T-cell redirection platform into solid tumors where PSMA is a well-validated antigen already exploited by approved radioligand therapies. APVO455 engages Nectin-4 x CD3, pursuing a target validated by the approved antibody-drug conjugate enfortumab vedotin in urothelial carcinoma. Both APVO442 and APVO455 are in earlier development stages relative to mipletamig. APVO451 and APVO452 are trispecific assets in preclinical development.
Recent Developments
On January 9, 2026, Aptevo closed a $60 million equity line of credit with Yorkville Advisors Global, extending the company's funding runway into 2029 alongside existing cash. As of March 31, 2026, cash and cash equivalents stood at $14.5 million. The Q1 2026 business update confirmed the RAINIER trial remains on schedule to complete and select a Phase II dose by end of 2026. Effective April 1, 2026, Jeff Lamothe was promoted from COO to President and CEO, with founder-era CEO Marvin White transitioning to Executive Chair.
Key Personnel
Jeff Lamothe serves as President and CEO, having been promoted from COO effective April 1, 2026, following Marvin White's transition to Executive Chair. White has led the company since its 2016 spin-off from Emergent BioSolutions and retains board-level oversight as Executive Chair. Lamothe's operational background from the COO role positions him to manage the RAINIER program through its critical Phase II dose-selection readout.
Strategic Partnerships
The most significant financing arrangement is the $60 million equity line of credit established with Yorkville Advisors Global in January 2026, structured to support both ongoing clinical development of mipletamig and advancement of the preclinical portfolio. Aptevo does not have publicly disclosed major pharma co-development partnerships at this stage, making the ELOC facility the primary mechanism for funding pipeline progression through the 2026 RAINIER readout and beyond.
FAQ Section
The frontline AML space is increasingly crowded following venetoclax-azacitidine's approval, and the commercial question is whether mipletamig can improve on — or deepen — that regimen's responses rather than replace it. An 81% CR/CRi rate in a triplet combination is a striking early signal, but RAINIER is an uncontrolled Phase Ib/II study, and comparisons to the historical ven-aza doublet must be made cautiously without a randomized arm. The absence of cytokine release syndrome in frontline patients is the distinctive safety feature that, if it holds, separates mipletamig from earlier CD3-bispecific attempts in AML.
CD123, the IL-3 receptor alpha chain, is overexpressed on AML blasts and — critically — on leukemic stem cells that are thought to drive relapse after conventional therapy. Engaging CD123 with a CD3-bispecific recruits T cells to eliminate these stem-like populations that chemotherapy and even ven-aza can miss. Venetoclax and azacitidine are already the established backbone for unfit patients; layering a T-cell redirector onto that regimen is designed to address residual disease rather than compete with a proven doublet.
The ADAPTIR architecture is engineered specifically to modulate the T-cell activation signal in a way intended to reduce the cytokine storm risk that has been the primary tolerability obstacle for CD3-engaging bispecifics, particularly in hematology. The clinical evidence so far — no cytokine release syndrome and no dose-limiting toxicities in the RAINIER frontline cohort — is consistent with that design intent, though the dataset remains early. The platform's modularity also supports the construction of trispecific formats, as demonstrated by APVO451 and APVO452, extending the potential therapeutic reach beyond binary antigen targeting.
The most material near-term event is dose selection for the Phase II expansion cohort, which Aptevo has guided will occur by year-end 2026. That decision will effectively define the clinical and regulatory path forward for mipletamig and determine whether the early response rates hold across a broader patient population. Any update on minimal residual disease negativity rates or duration of response data from the Phase Ib cohort would also sharpen the commercial and partnering case considerably.
Beyond mipletamig, Aptevo has two bispecific assets targeting solid tumors: APVO442 (PSMA x CD3) in prostate cancer and APVO455 (Nectin-4 x CD3) in urothelial and other Nectin-4-expressing tumors. Both targets have precedent — PSMA-directed radioligand therapies and enfortumab vedotin respectively — which validates the antigen but also signals competitive intensity. Both assets are in earlier development than mipletamig, and Aptevo's limited cash position means RAINIER will remain the clinical and capital priority through at least end of 2026.
Aptevo is a clinical-stage company with its lead asset in Phase Ib/II and its broader portfolio at preclinical or early clinical stages. Cash on hand was $14.5 million as of March 31, 2026 — a thin balance — but the $60 million equity line of credit with Yorkville Advisors, closed in January 2026, extends the funding runway into 2029 if drawn upon progressively. The ELOC structure means dilution risk is real and ongoing, which investors should weigh against the clinical catalysts expected through 2026 and 2027.
The RAINIER readout and the equity financing structure define Aptevo's near-term risk-reward profile. Key watchpoints include:
Latest Aptevo Therapeutics News
Today's issue
| Headless Content Management with Blaze